Little Clinic announces opening of new location in a Miami-area Publix
BRENTWOOD, Tenn. The Little Clinic, an operator of in-store health clinics, has announced the opening of its eighth convenient care clinic in the Miami area inside Publix. Six additional Miami-area clinics are under construction and will open later this year.
“The Little Clinic is excited to expand our services throughout Miami,” said John Grzybowski, Chief Operating Officer. “Our growth will allow us the opportunity to provide more consumers with quality, time efficient, affordable healthcare.”
The existing clinics operated by The Little Clinic throughout Miami include locations within the following area Publix stores:
On April 16, The Little Clinic opened a new clinic in the Tampa area inside Publix. The Palm Harbor clinic joins the seven existing clinics operating around Tampa, bringing the clinic total in the market to eight.
Amgen, Wyeth revise labeling for Enbrel
PHILADELPHIA and THOUSAND OAKS, Calif. Amgen and Wyeth Pharmaceuticals have informed health care professionals of revisions to prescribing information for their rheumatoid arthritis and psoriasis medication Enbrel.
The revisions include a boxed warning about infections, including serious infections leading to hospitalization or death that have been observed in patients treated with Enbrel.
Infections have included bacterial sepsis and tuberculosis. The adverse reactions section of the label was updated to include information regarding global clinical studies and the rate of occurrence of tuberculosis in patients treated with Enbrel.
FDA approves Advair for wider use with COPD patients
WASHINGTON The Food and Drug Administration has approved GlaxoSmithKline’s asthma drug Advair to be used more widely to treat patients with chronic obstructive pulmonary disease, according to published reports. The drug had been approved to prevent wheezing and control other symptoms in COPD patients.
GSK’s approval comes the same day as rival AstraZeneca said it also was seeking FDA approval to sell its drug Symbicort for COPD.
COPD, an often-fatal lung condition with no cure, is a major market with more than 12 million Americans suffering from the disease, and another 12 million who are likely not diagnosed, according to the National Institutes of Health.
The FDA’s approval allows GSK to promote its product to COPD patients who experience flare-ups of the disease, which includes emphysema and chronic bronchitis.